"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients ...

today announced new positive data from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel), in patients with relapsed or refractory multiple myeloma (RRMM). These data ...

The following is a summary of “Retrospective analysis of treatment discontinuation in minimal residual disease negative multiple myeloma,” published in the March 2025 issue of International Journal of ...

The multiple myeloma armamentarium is large and getting larger. That makes treatment choices complex and the cost of ...

Researchers uncover corneal changes in multiple myeloma patients treated with belantamab mafodotin, revealing potential ...

There was also a trend towards improved overall survival (OS) in the study, which involved patients with relapsed/refractory multiple myeloma previously treated with at least one prior line of ...

Over 80% of patients with relapsed/refractory multiple myeloma responded to anti-GPRC5D CAR T-cell therapy after failure of anti-BCMA CAR T-cell therapy. The investigational therapy showed ...

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today ...